March 19, 2012 -- Zhejiang Hisoar Pharmaceutical received approval from Japan to sell its API for meropenem, a beta-lactam antibiotic, in that country. The company’s Chuannan subsidiary was awarded a GMP compliance certificate by Japanese regulators. Hisoar said the approval will have a positive effect on the company’s performance, though it did not quantify the expected gain in revenue. More details....
Stock Symbol: (SHE: 002099)